The US FDA recently granted Breakthrough Therapy Designations for two investigational targeted therapies (amivantamab [JNJ-372] [12] and mobocertinib [TAK-788] [13]) for the treatment of patients with metastatic NSCLC with EGFR Exon 20ins mutation whose disease has progressed on or after platinum-based chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.